Quantcast
Last updated on April 18, 2014 at 16:58 EDT

Latest Bronchopulmonary dysplasia Stories

2014-01-29 11:16:30

Children who are born preterm have an increased risk developing asthma and wheezing disorders during childhood according to new research published in PLOS Medicine. The research by Jasper Been, from the Maastricht University Medical Centre (Netherlands) and The University of Edinburgh (UK), and colleagues at Harvard Medical School (US) is a systematic review and meta-analysis of 30 unique studies that collectively involved approximately 1.5 million children. The authors found that children...

2013-08-15 14:44:34

A neonatologist at The Children's Hospital of Philadelphia is the senior author of a large new study that found that current non-invasive techniques for respiratory support are less effective than widely assumed, in reducing the incidence of severe lung injury in very premature infants. Neonatologists commonly use non-invasive nasal ventilation instead of mechanical ventilation via a breathing tube, in hopes of avoiding bronchopulmonary dysplasia (BPD). Frequently a by-product of...

2013-07-03 15:04:34

LA BioMed research finds substance in turmeric provides lasting protection Turmeric, a key ingredient in spicy curry dishes, has long been known to have medicinal values. Now new research finds a substance in turmeric, curcumin, may provide lasting protection against potentially deadly lung damage in premature infants. Premature infants often need the assistance of ventilators and forced oxygen therapy because they're frequently born with inadequate lung function. These therapies can...

2013-06-11 08:30:34

Follow-up SURFAXIN® (lucinactant) Data Analysis Presented at 2013 Pediatric Pharmacy Advocacy Group Annual Meeting WARRINGTON, Pa., June 11, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of the last in a series of pharmacoeconomic analyses indicating that a reduction in the rate of reintubation( )among preterm infants may potentially result in hospital cost-savings related to fewer reintubation-related diagnoses of...

2012-12-04 12:48:35

For Ottawa scientist and neonatologist Dr. Bernard Th̩baud, even a major paper that answers five significant questions still doesn't seem quite enough in his determined path to get his laboratory breakthrough into the neonatal intensive care unit (NICU). Dr. Th̩baud's proposed therapy would use stem cells from umbilical cords to treat a disease previously thought to be untreatable Рbronchopulmonary dysplasia, or BPD. "BPD is a lung disease described 45...

2012-12-04 08:28:23

WARRINGTON, Pa., Dec. 4, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the release of data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with SURFAXIN(® )may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia (BPD) when compared with reintubation rates of infants...

2012-11-28 08:29:41

WARRINGTON, Pa., Nov. 28, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced it will present both SURFAXIN(®) and AFECTAIR(®) data at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C. Hot Topics in Neonatology is an internationally recognized medical meeting dedicated to advancing the practice of neonatology. Earlier this year, SURFAXIN became the first Food and Drug Administration (FDA)-approved synthetic,...

2012-05-01 02:31:29

WARRINGTON, Pa., May 1, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN(®), when compared with infants treated with Curosurf(®) and Survanta(®), the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants. The...

2012-02-27 09:17:00

HAMPTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD). The trial, which commenced in December 2009, enrolled its last patient six weeks ahead of schedule. The...

2011-06-13 15:28:46

Study shows that five guidelines for avoiding ventilators improve outcomes, reduce costs of care Guidelines that reduce the use of mechanical ventilation with premature infants in favor of a gentler form of respiratory support can profoundly affect those children's outcomes while reducing the cost of care, according to a team of researchers at Children's Hospital Boston. The team, led by Bernadette Levesque, MD, of the Division of Newborn Medicine at Children's Hospital Boston and the...